Bausch + Lomb price target raised to $19 from $18 at Barclays
Barclays raised the firm’s price target on Bausch + Lomb (BLCO) to $19 from $18 and keeps an Equal Weight rating on the shares. The firm says ...
ophthalmologytimes2d
InflammX Therapeutics enters option agreement with Bausch + Lomb, grants right to acquire the company
InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...
MM&M6d
Vicks retains top spot among Rx, OTC pharma brands in December
Vicks once again achieved the top monthly spot for TV impressions, while iSpot noted that pharma brands generated more year-over-year returns from sports and news cables compared to 2023.